We use our own cookies and third parties ones to offer our services and collect statistical data. If you continue browsing the internet you accept them. More information

Accept
Research Project

Clinical AATD clusters from the EARCO registry

Principal Investigator:
Stephanie Everaerts
Center:
University Hospitals Leuven
City/Country:
Leuven (Belgium)
Start date:
November 2022
Status:
Ongoing
Contact E-mail:
stephanie.everaerts@uzleuven.be
<br /> <b>Warning</b>: Use of undefined constant _ALT - assumed '_ALT' (this will throw an Error in a future version of PHP) in <b>/home/earco0/www/ficha_proyectos.php</b> on line <b>170</b><br /> _ALT

Introduction

AATD is, even within the same genotype, a very heterogeneous disease with large differences between patients. Cluster analyses are useful to recognize different clinical phenotypes  and to discover associations between different clinical features (eg. liver disease, emphysema, bronchiectasis, sex, asthma).

Objectives

The main objective is the recognition of different AATD clinical phenotypes by cluster analysis in baseline EARCO data.

In a second stage, these clusters could be linked to clinically relevant outcomes such as lung function decline and exacerbations.

 

Inclusion criteria

Baseline data from the EARCO registry will be used. All registered patients from the launch in february 2020 to start of analysis will be eligible for cluster analysis. 

 

Brief summary

Baseline data from the EARCO registry will be used for cluster analysis. Different methods will be tested to obtain the best model. Cluster analyses are useful to recognize different clinical phenotypes and to discover associations between different clinical features. This is useful since AATD is a very heterogeneous disease, even within the same genotype.